Language:
English
繁體中文
Help
Login
Back
Switch To:
Labeled
|
MARC Mode
|
ISBD
Evaluation of enzyme inhibitors in d...
~
Copeland, Robert Allen.
Evaluation of enzyme inhibitors in drug discovery = a guide for medicinal chemists and pharmacologists /
Record Type:
Language materials, printed : Monograph/item
Title/Author:
Evaluation of enzyme inhibitors in drug discovery/ Robert A. Copeland.
Reminder of title:
a guide for medicinal chemists and pharmacologists /
Author:
Copeland, Robert Allen.
Published:
Hoboken, N.J. :Wiley, : c2013.,
Description:
1 online resource (xxxi, 538 p.)
Subject:
Enzyme inhibitors - Therapeutic use -
Online resource:
http://onlinelibrary.wiley.com/book/10.1002/9781118540398
ISBN:
9781118540404 (electronic bk.)
Evaluation of enzyme inhibitors in drug discovery = a guide for medicinal chemists and pharmacologists /
Copeland, Robert Allen.
Evaluation of enzyme inhibitors in drug discovery
a guide for medicinal chemists and pharmacologists /[electronic resource] :Robert A. Copeland. - 2nd ed. - Hoboken, N.J. :Wiley,c2013. - 1 online resource (xxxi, 538 p.)
Includes bibliographical references and index.
"There has been explosive growth in the hunt for new pharmaceutically agents globally. Traditionally, this has been the purview of the pharmaceutical industry, but today, this effort crosses academic, government, and industry laboratories across the world. Enzymes remain the most valued and common of drug targets; hence, a detailed understanding of their interactions with inhibitors is critical to successful drug discovery. This book provides a practical, readable, and comprehensive treatment of these topics that allows scientists to master the art of applied enzymology for drug discovery. The book addresses the opportunities for inhibitor interactions with enzyme targets arising from consideration of the catalytic reaction mechanism; discusses how inhibitors are properly evaluated for potency, selectivity, and mode of action, covers the potential advantages and liabilities of specific inhibition modalities with respect to efficacy in vivo, and provides valuable biochemical insights to help medicinal chemists and pharmacologists most effectively pursue lead optimization. It includes two new chapters, one on the pioneering idea of drug-target residence time fostered by Dr. Copeland, and the second on quantitative biochemistry. Five new appendices are added"--Provided by publisher.
ISBN: 9781118540404 (electronic bk.)
LCCN: 2012046209Subjects--Topical Terms:
1000396
Enzyme inhibitors
--Therapeutic use
LC Class. No.: QP601.5 / .C675 2013
Dewey Class. No.: 615/.19
National Library of Medicine Call No.: QU 143
Evaluation of enzyme inhibitors in drug discovery = a guide for medicinal chemists and pharmacologists /
LDR
:02762cam a2200397 a 4500
001
795578
003
OCoLC
005
20130806030035.0
006
m o d
007
cr |||||||||||
008
150505s2013 nju ob 001 0 eng
010
$a
2012046209
020
$a
9781118540404 (electronic bk.)
020
$a
1118540409 (electronic bk.)
020
$a
9781118540282 (electronic bk.)
020
$a
111854028X (electronic bk.)
020
$z
9781118354483 (electronic bk.)
020
$z
1118354486 (electronic bk.)
020
$a
9781118540398 (electronic bk.)
020
$a
1118540395 (electronic bk.)
020
$z
9781118540299
020
$z
1118540298
020
$z
9781118488133 (hardback)
035
$a
(OCoLC)818327396
035
$a
ocn818327396
040
$a
DLC
$b
eng
$c
DLC
$d
YDX
$d
EBLCP
$d
N
$d
E7B
$d
YDXCP
$d
OCLCO
$d
DG1
$d
IDEBK
$d
DG1
$d
STF
$d
DG1
$d
UBY
050
4
$a
QP601.5
$b
.C675 2013
060
1 0
$a
QU 143
082
0 0
$a
615/.19
$2
23
100
1
$a
Copeland, Robert Allen.
$3
1000395
245
1 0
$a
Evaluation of enzyme inhibitors in drug discovery
$h
[electronic resource] :
$b
a guide for medicinal chemists and pharmacologists /
$c
Robert A. Copeland.
250
$a
2nd ed.
260
$a
Hoboken, N.J. :
$b
Wiley,
$c
c2013.
300
$a
1 online resource (xxxi, 538 p.)
504
$a
Includes bibliographical references and index.
520
$a
"There has been explosive growth in the hunt for new pharmaceutically agents globally. Traditionally, this has been the purview of the pharmaceutical industry, but today, this effort crosses academic, government, and industry laboratories across the world. Enzymes remain the most valued and common of drug targets; hence, a detailed understanding of their interactions with inhibitors is critical to successful drug discovery. This book provides a practical, readable, and comprehensive treatment of these topics that allows scientists to master the art of applied enzymology for drug discovery. The book addresses the opportunities for inhibitor interactions with enzyme targets arising from consideration of the catalytic reaction mechanism; discusses how inhibitors are properly evaluated for potency, selectivity, and mode of action, covers the potential advantages and liabilities of specific inhibition modalities with respect to efficacy in vivo, and provides valuable biochemical insights to help medicinal chemists and pharmacologists most effectively pursue lead optimization. It includes two new chapters, one on the pioneering idea of drug-target residence time fostered by Dr. Copeland, and the second on quantitative biochemistry. Five new appendices are added"--Provided by publisher.
588
$a
Description based on online resource; title from digital title page (viewed on Apr. 25, 2013).
650
0
$a
Enzyme inhibitors
$x
Therapeutic use
$x
Testing.
$3
1000396
650
0
$a
Drugs
$x
Design.
$3
582269
650
0
$a
Enzyme inhibitors
$x
Structure-activity relationships.
$3
1000397
650
2
$a
Enzyme Inhibitors
$x
therapeutic use.
$3
1000398
650
2
$a
Drug Design.
$3
557397
650
2
$a
Enzyme Inhibitors
$x
chemistry.
$3
1000399
856
4 0
$u
http://onlinelibrary.wiley.com/book/10.1002/9781118540398
based on 0 review(s)
Multimedia
Reviews
Add a review
and share your thoughts with other readers
Export
pickup library
Processing
...
Change password
Login